...
atra-img

Atara Biotherapeutics Inc, Common Stock

ATRA

NSQ

$10.5

+$0.15

(1.45%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$59.61M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
8.76K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.49
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.5 L
$39.5 H
$10.5

About Atara Biotherapeutics Inc, Common Stock

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATRASectorS&P500
1-Week Return-15.06%-3.39%0.2%
1-Month Return-8.65%-1.92%2.72%
3-Month Return21.62%-10.54%7.31%
6-Month Return-2.47%-4.47%10.44%
1-Year Return-27.69%4.06%27.53%
3-Year Return-97.27%0.94%30.88%
5-Year Return-97.31%36.67%89.21%
10-Year Return-98.63%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-3.55M20.34M63.57M8.57M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.59,"profit":true},{"date":"2021-12-31","value":31.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.49,"profit":true}]
Cost of Revenue8.11M9.87M11.38M14.57M8.89M[{"date":"2019-12-31","value":55.64,"profit":true},{"date":"2020-12-31","value":67.73,"profit":true},{"date":"2021-12-31","value":78.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61,"profit":true}]
Gross Profit(8.11M)(9.87M)20.34M49.01M(313.00K)[{"date":"2019-12-31","value":-16.54,"profit":false},{"date":"2020-12-31","value":-20.13,"profit":false},{"date":"2021-12-31","value":41.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-0.64,"profit":false}]
Gross Margin(Infinity%)(277.79%)100.00%77.08%(3.65%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-277.79,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.08,"profit":true},{"date":"2023-12-31","value":-3.65,"profit":false}]
Operating Expenses295.68M309.05M360.80M344.09M275.69M[{"date":"2019-12-31","value":81.95,"profit":true},{"date":"2020-12-31","value":85.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.37,"profit":true},{"date":"2023-12-31","value":76.41,"profit":true}]
Operating Income(295.68M)(309.05M)(340.46M)(280.51M)(276.01M)[{"date":"2019-12-31","value":-29568100000,"profit":false},{"date":"2020-12-31","value":-30905200000,"profit":false},{"date":"2021-12-31","value":-34046200000,"profit":false},{"date":"2022-12-31","value":-28051300000,"profit":false},{"date":"2023-12-31","value":-27600600000,"profit":false}]
Total Non-Operating Income/Expense9.43M4.89M734.00K54.21M839.00K[{"date":"2019-12-31","value":17.4,"profit":true},{"date":"2020-12-31","value":9.03,"profit":true},{"date":"2021-12-31","value":1.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.55,"profit":true}]
Pre-Tax Income(290.96M)(306.61M)(340.10M)(228.29M)(276.11M)[{"date":"2019-12-31","value":-29096400000,"profit":false},{"date":"2020-12-31","value":-30660500000,"profit":false},{"date":"2021-12-31","value":-34009500000,"profit":false},{"date":"2022-12-31","value":-22829000000,"profit":false},{"date":"2023-12-31","value":-27611100000,"profit":false}]
Income Taxes12.00K15.00K46.00K12.00K15.00K[{"date":"2019-12-31","value":26.09,"profit":true},{"date":"2020-12-31","value":32.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.09,"profit":true},{"date":"2023-12-31","value":32.61,"profit":true}]
Income After Taxes(290.98M)(306.62M)(340.14M)(228.30M)(276.13M)[{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-22830200000,"profit":false},{"date":"2023-12-31","value":-27612600000,"profit":false}]
Income From Continuous Operations(290.98M)(306.62M)(340.14M)(228.30M)(290.25M)[{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-22830200000,"profit":false},{"date":"2023-12-31","value":-29024800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(290.98M)(306.62M)(340.14M)(2.28B)(276.13M)[{"date":"2019-12-31","value":-29097600000,"profit":false},{"date":"2020-12-31","value":-30662000000,"profit":false},{"date":"2021-12-31","value":-34014100000,"profit":false},{"date":"2022-12-31","value":-228302000000,"profit":false},{"date":"2023-12-31","value":-27612600000,"profit":false}]
EPS (Diluted)(5.71)(4.21)(3.63)(2.72)(2.62)[{"date":"2019-12-31","value":-571,"profit":false},{"date":"2020-12-31","value":-421,"profit":false},{"date":"2021-12-31","value":-363,"profit":false},{"date":"2022-12-31","value":-272,"profit":false},{"date":"2023-12-31","value":-262,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATRA
Cash Ratio 0.43
Current Ratio 0.59
Quick Ratio 0.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATRA
ROA (LTM) -57.48%
ROE (LTM) -2014.86%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATRA
Debt Ratio Lower is generally better. Negative is bad. 1.63
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATRA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.96
P/B 1.97
Price/FCF NM
EV/R 0.42
EV/Ebitda NM
PEG NM

FAQs

What is Atara Biotherapeutics Inc share price today?

Atara Biotherapeutics Inc (ATRA) share price today is $10.5

Can Indians buy Atara Biotherapeutics Inc shares?

Yes, Indians can buy shares of Atara Biotherapeutics Inc (ATRA) on Vested. To buy Atara Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Atara Biotherapeutics Inc be purchased?

Yes, you can purchase fractional shares of Atara Biotherapeutics Inc (ATRA) via the Vested app. You can start investing in Atara Biotherapeutics Inc (ATRA) with a minimum investment of $1.

How to invest in Atara Biotherapeutics Inc shares from India?

You can invest in shares of Atara Biotherapeutics Inc (ATRA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATRA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Atara Biotherapeutics Inc shares
What is Atara Biotherapeutics Inc 52-week high and low stock price?

The 52-week high price of Atara Biotherapeutics Inc (ATRA) is $39.5. The 52-week low price of Atara Biotherapeutics Inc (ATRA) is $6.5.

What is Atara Biotherapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Atara Biotherapeutics Inc (ATRA) is

What is Atara Biotherapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Atara Biotherapeutics Inc (ATRA) is 1.97

What is Atara Biotherapeutics Inc dividend yield?

The dividend yield of Atara Biotherapeutics Inc (ATRA) is 0.00%

What is the Market Cap of Atara Biotherapeutics Inc?

The market capitalization of Atara Biotherapeutics Inc (ATRA) is $59.61M

What is Atara Biotherapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Atara Biotherapeutics Inc is ATRA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top